Indivior PLC announced that it was added to the S&P SmallCap 600 index on December 22, 2025, following earlier inclusions in the S&P 1000 and the S&P Pharmaceuticals Select Industry Index and ...

RICHMOND, Va., Oct. 7, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the Prior Approval Supplement (PAS) for SUBLOCADE® (buprenorphine extended-release) injection submitted by ...

For my penultimate Barchart article in 2025, I wanted to revisit Indivior (INDV), a Virginia-based developer of opioid ...

SUBLOCADE Year-over-Year Growth: Expected to show 17% growth at the midpoint for fiscal year 2024. SUBLOCADE Net Revenue Forecast: Revised guidance due to increased competition and market dynamics.

Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE® Net Revenue Expected to be in the Range of $905 ...

RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...

Indivior PLC (NASDAQ:INDV) is one of the best performing pharma stocks in 2025. Indivior PLC (NASDAQ:INDV) announced its full ...

Indivior PLC (NASDAQ:INDV) shares are trading lower after the company reported preliminary third-quarter revenue results and cut its FY24 net revenue guidance below estimates. The company expects ...

(RTTNews) - Indivior PLC (INDV, INDV.L), a specialty pharmaceutical company, announced Wednesday that the U.S. Food and Drug Administration has informed that the final review of the SUBLOCADE ...

Franklin County Municipal Court is now offering onsite treatment for monthly medication-assisted treatments for opioid ...

CEO Mark Crossley stated that Q1 financial results were in line with expectations, despite a 6% year-on-year decline in total net revenue, largely driven by intensified competition in SUBOXONE Film ...